secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-04-07T23:59:59+00:00
Accession:  0001104659-26-040387
Event type: regulatory
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics FDA accepts FDRR for ONS-5010; meeting set for April 2026
------------------------------------------------------------------------------

- FDA accepted Formal Dispute Resolution Request for ONS-5010/LYTENAVA (bevacizumab) for wet AMD.
- Meeting with deciding official scheduled for April 2026; follows Type A meeting on March 2, 2026.
- Company cites NORSE TWO and NORSE EIGHT data supporting efficacy/safety; no safety concerns raised.
- If approved, ONS-5010 would be first FDA-approved ophthalmic bevacizumab with standardized manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926040387/0001104659-26-040387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926040387/tm2611268d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-040387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer